NBIX
Price
$143.03
Change
+$5.49 (+3.99%)
Updated
May 1, 6:59 PM EST
89 days until earnings call
SUPN
Price
$30.08
Change
-$0.02 (-0.07%)
Updated
May 1, 6:59 PM EST
6 days until earnings call
Ad is loading...

Analysis and predictions NBIX vs SUPN

Header iconNBIX vs SUPN Comparison
Open Charts NBIX vs SUPNBanner chart's image
Neurocrine Biosciences
Price$143.03
Change+$5.49 (+3.99%)
Volume$783.74K
CapitalizationN/A
Supernus Pharmaceuticals
Price$30.08
Change-$0.02 (-0.07%)
Volume$186.37K
CapitalizationN/A
View a ticker or compare two or three
NBIX vs SUPN Comparison Chart

Loading...

NBIXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SUPNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
NBIX vs. SUPN commentary
May 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBIX is a Buy and SUPN is a StrongSell.

COMPARISON
Comparison
May 02, 2024
Stock price -- (NBIX: $143.18 vs. SUPN: $30.06)
Brand notoriety: NBIX and SUPN are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: NBIX: 162% vs. SUPN: 81%
Market capitalization -- NBIX: $13.72B vs. SUPN: $1.84B
NBIX [@Pharmaceuticals: Other] is valued at $13.72B. SUPN’s [@Pharmaceuticals: Other] market capitalization is $1.84B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whileSUPN’s FA Score has 1 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • SUPN’s FA Score: 1 green, 4 red.
According to our system of comparison, NBIX is a better buy in the long-term than SUPN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBIX’s TA Score shows that 7 TA indicator(s) are bullish while SUPN’s TA Score has 6 bullish TA indicator(s).

  • NBIX’s TA Score: 7 bullish, 3 bearish.
  • SUPN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than SUPN.

Price Growth

NBIX (@Pharmaceuticals: Other) experienced а +3.03% price change this week, while SUPN (@Pharmaceuticals: Other) price change was -0.66% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.82%. For the same industry, the average monthly price growth was +30.06%, and the average quarterly price growth was +18979.84%.

Reported Earning Dates

NBIX is expected to report earnings on Jul 30, 2024.

SUPN is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (+3.82% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for NBIX with price predictions.
OPEN
A.I.dvisor published
a Summary for SUPN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NBIX($13.7B) has a higher market cap than SUPN($1.84B). SUPN has higher P/E ratio than NBIX: SUPN (1677.00) vs NBIX (57.20). NBIX YTD gains are higher at: 8.663 vs. SUPN (3.870). NBIX has higher annual earnings (EBITDA): 358M vs. SUPN (90M). NBIX has more cash in the bank: 1.03B vs. SUPN (255M). SUPN has less debt than NBIX: SUPN (41.5M) vs NBIX (428M). NBIX has higher revenues than SUPN: NBIX (1.89B) vs SUPN (608M).
NBIXSUPNNBIX / SUPN
Capitalization13.7B1.84B746%
EBITDA358M90M398%
Gain YTD8.6633.870224%
P/E Ratio57.201677.003%
Revenue1.89B608M310%
Total Cash1.03B255M405%
Total Debt428M41.5M1,031%
FUNDAMENTALS RATINGS
NBIX vs SUPN: Fundamental Ratings
NBIX
SUPN
OUTLOOK RATING
1..100
6812
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
34100
SMR RATING
1..100
6489
PRICE GROWTH RATING
1..100
4756
P/E GROWTH RATING
1..100
891
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (83) in the Biotechnology industry is in the same range as SUPN (99) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to SUPN’s over the last 12 months.

NBIX's Profit vs Risk Rating (34) in the Biotechnology industry is significantly better than the same rating for SUPN (100) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew significantly faster than SUPN’s over the last 12 months.

NBIX's SMR Rating (64) in the Biotechnology industry is in the same range as SUPN (89) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to SUPN’s over the last 12 months.

NBIX's Price Growth Rating (47) in the Biotechnology industry is in the same range as SUPN (56) in the Pharmaceuticals Other industry. This means that NBIX’s stock grew similarly to SUPN’s over the last 12 months.

SUPN's P/E Growth Rating (1) in the Pharmaceuticals Other industry is significantly better than the same rating for NBIX (89) in the Biotechnology industry. This means that SUPN’s stock grew significantly faster than NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBIXSUPN
RSI
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
60%
Bullish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 1 day ago
68%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bearish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 10 days ago
72%
Bullish Trend 4 days ago
70%
Declines
ODDS (%)
Bearish Trend 7 days ago
62%
Bearish Trend 1 day ago
68%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
65%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Ad is loading...
NBIXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SUPNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CMCM4.060.15
+3.84%
Cheetah Mobile
PLSE7.600.23
+3.12%
Pulse Biosciences
ASND140.922.48
+1.79%
Ascendis Pharma A/S
STAA44.66-1.30
-2.83%
STAAR Surgical Company
GROM0.57-0.05
-7.51%
Grom Social Enterprises

NBIX and

Correlation & Price change

A.I.dvisor tells us that NBIX and ITCI have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and ITCI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
+4.10%
ITCI - NBIX
31%
Poorly correlated
+1.19%
ACET - NBIX
25%
Poorly correlated
+1.34%
PCRX - NBIX
25%
Poorly correlated
+2.67%
SUPN - NBIX
24%
Poorly correlated
-0.13%
SNDL - NBIX
23%
Poorly correlated
-10.12%
More

SUPN and

Correlation & Price change

A.I.dvisor tells us that SUPN and SIGA have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SUPN and SIGA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SUPN
1D Price
Change %
SUPN100%
-0.13%
SIGA - SUPN
33%
Poorly correlated
+6.15%
COLL - SUPN
31%
Poorly correlated
+2.30%
AMPH - SUPN
30%
Poorly correlated
+1.92%
SNDL - SUPN
27%
Poorly correlated
-10.12%
ACET - SUPN
27%
Poorly correlated
+1.34%
More